RT Journal Article
SR Electronic
T1 Role of monocytes in endothelial glycocalyx shedding during Puumala orthohantavirus infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.25.24312546
DO 10.1101/2024.08.25.24312546
A1 Cabrera, Luz E.
A1 Polanco, Isaac
A1 Tietäväinen, Johanna
A1 Mäkelä, Satu
A1 Vapalahti, Olli
A1 Vaheri, Antti
A1 Mustonen, Jukka
A1 Strandin, Tomas
YR 2024
UL http://medrxiv.org/content/early/2024/08/26/2024.08.25.24312546.abstract
AB Vascular leakage characterizes Puumala orthohantavirus (PUUV)-caused hemorrhagic fever with renal syndrome (HFRS). Disruption in the endothelial glycocalyx layer, which protects blood vessels from increased vascular leakage into tissues, may contribute to disease severity during acute PUUV-HFRS. Recent evidence suggests that increased heparanase (HPSE) activity could play a role in glycocalyx degradation. Additionally, dynamic changes in monocyte populations, especially a decrease in endothelium “patrolling” CD14+CD16+ nonclassical monocytes (NCMs) are observed in acute PUUV-HFRS. To investigate HPSE expression levels in different monocyte subsets and their relationship to the numbers of circulating endothelial cells (CECs) as marker of glycocalyx degradation during PUUV-HFRS, we analyzed patient peripheral blood mononuclear cells collected at acute and recovery stages of the disease by flow cytometry. CECs were significantly increased in acute PUUV-HFRS patients, and gradually decreased towards the postacute and recovery phases. Moreover, we identified significant correlations between CECs, the frequencies of different monocyte subsets and their HPSE expression, and clinical parameters. The decrease in HPSE expressing NCMs correlated with plasma HPSE levels, indicating a potential role for monocytes in modulating endothelial glycocalyx shedding. Furthermore, co-culture experiments suggested PUUV-infected endothelial cells (ECs) as regulators of monocyte HPSE expression. The study enhances understanding of EC and monocyte dynamics during PUUV-HFRS, providing insights into immune responses and potential vascular complications. Subtle variations in monocyte subsets emphasize their possible variable roles in disease progression and changes throughout the disease course. Overall, the study contributes to unraveling the complex interactions between viral infections, immune responses, and vascular dynamics, guiding future investigations and interventions in PUUV-HFRS-associated vascular complications and glycocalyx shedding in the kidneys.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financed by grants by the Academy of Finland to T.S. (321809); grants by the Helsinki University Hospital funds to O.V. (TYH 2021343); EU Horizon 2020 programme VEO (874735) to O.V.; Paulo foundation to L.E.C.; Finnish medical foundation to L.E.C.; Finnish Kidney Foundation to L.E.C. and J.T.; Jane and Aatos Erkko foundation to O.V.; and Finnish Cultural Foundation Pirkanmaa Regional fund to J.T. The funders had no role in study design, data collection and analysis, nor decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Tampere University Hospital gave ethical approval for this work. Ethics committee of Hospital District of Helsinki and Uusimaa gave ethical approval for this work. All subjects gave written informed consent in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors